Thus, our findings extend the understanding of m6A-driven machinery in acral melanoma progression and proposed that the METTL3-m6A-TXNDC5 axis may serve as biomarker and therapeutic strategy in the clinic. This evidence concerns the gene METTL3 and acral lentiginous melanoma.